Can a Dual-Action diabetes drug prevent dangerous clots?

NCT ID NCT06618976

Completed Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether sotagliflozin, a dual SGLT1/2 inhibitor, reduces blood clot formation better than empagliflozin, a standard SGLT2 inhibitor. Seventeen healthy volunteers took each drug for one month in a crossover design. Researchers measured clot size and platelet activity in the lab to see if sotagliflozin offers extra protection against thrombosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sotagliflozin and Empagliflozin
What this could lead to: If sotagliflozin reduces clot formation more than empagliflozin, it could point toward a safer treatment option for heart patients at risk of blood clots.
What could go wrong: This was a very small study in 17 healthy people, not patients, so results may not apply to real-world heart disease. It only measured lab markers of clotting, not actual heart attacks or strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOSIS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.